BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2018-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test safety and anti-tumor activity of BT062 in combination
with lenalidomide and dexamethasone to define the best doses for treating patients with
relapsed and refractory multiple myeloma.